The CARAT-2 clinical data, which were first presented and announced in 2011 at the American College of Rheumatology, are now available in an online article in the Annals of the Rheumatic Diseases titled, "Chemokine receptor CCR1
antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial" The findings also will be presented in an oral presentation titled, "Orally Administered CCR1
Antagonist CCX354-C in Phase 2 Rheumatoid Arthritis Study," on June 9th at the Annual European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology being held in Berlin.
The current nomenclature is thus based on these families, eg, CCL1 for ligand 1 of the CC family of chemokines and CCR1
for its respective receptor.
51) Therefore, CCR1
might simply have been the wrong target in MS.
The [3-68] variant form of RANTES was subsequently found to also inhibit HIV to the same degree but to lack the same binding affinity to the CCR1
0 million option exercise fee received from GSK in 2011 for the exclusive license to further develop and commercialize CCX354, our CCR1
1:45: EXPRESSION AND LOCALIZATION OF RANTES AND CORRESPONDING RECEPTORS CCR1
, CCR3, AND CCR5 IN PLASMODIUM YOELII INFECTED MOUSE BRAIN, Bismark Y.
Chemokine Receptor (CCR1
): Ligand is conducting preclinical development from the internal chemokine receptor CCR1
today announced that GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive license for further development and worldwide commercialization of the investigational medicine CCX354, a potent and selective inhibitor of CCR1
, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis (RA).
Separately, ChemoCentryx and Forest Laboratories entered into a collaboration to co-develop small molecule antagonists targeting the CCR1
receptor for the treatment of autoimmune diseases such as rheumatoid arthritis.
Earlier this year, ChemoCentryx announced the formation of a co-development collaboration with Forest Laboratories for the company's oral CCR1
receptor antagonist for the treatment of inflammatory diseases such as rheumatoid arthritis and multiple sclerosis.
CCX354 is an orally-active small molecule that specifically targets and inhibits the chemokine receptor known as CCR1
, which is implicated in the development and progression of rheumatoid arthritis (RA).
The collaboration focuses on CCR1
, a specific chemokine receptor involved in inflammation.